Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Blood|2021Cited by 4
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphomaAnnie Xiao, Brian Lee, Matthew Mei et al.|Leukemia & lymphoma/Leukemia and lymphoma|2025Cited by 3